A Potential Analgesic Target in a Novel Clinically-Relevant Neuropathic Pain Pathway.

Grant number: 1099930 | Funding period: 2016 - 2018

Completed

Abstract

Persistent pain arising from tissue damage, to nerves, muscles or joints for example, is devastating for patients and a huge social and economic burden. This work will investigate one of the pathways that goes awry after sensory nerves are damaged. These experiments will also test whether a drug being developed to treat Alzheimer's disease is effective at blocking the persistent nerve hypersensitivity that sometimes develops after injury.

Related publications (2)

The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases

WQ Qiu, S Luo, SA Ma, P Saminathan, H Li, JM Gunnersen, HA Gelbard, JW Hammond

2021-04-15

The Sez6 family consists of Sez6, Sez6L, and Sez6L2. Its members are expressed throughout the brain and have been shown to influen..

Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6

K Zhu, X Xiang, S Filser, P Marinković, MM Dorostkar, S Crux, U Neumann, DR Shimshek, G Rammes, C Haass, SF Lichtenthaler, JM Gunnersen, J Herms

2018-03-01

Background: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a promising drug target for the treatment of Alzheime..

University of Melbourne Researchers

Jenny Gunnersen

Stuart McDougall